Johnson & Johnson’s FcRn blocker nipocalimab meets Phase 2 primary endpoint in systemic lupus

 

Johnson & Johnson’s FcRn blocker nipocalimab meets Phase 2 primary endpoint in systemic lupus erythematosus

• Phase 2 JASMINE trial in moderate-to-severe systemic lupus erythematosus showed sustained 52-week reductions in disease activity.
• JASMINE results support ongoing Phase 3 development of nipocalimab in systemic lupus erythematosus.
• Phase 2 DAHLIAS data show nipocalimab boosts responses in autoantibody-high Sjögren’s disease, supporting a Phase 3 program.

https://finviz.com/stock?t=JNJ&p=d